Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentOpen to AccrualParticipants Off Study and Primary Analysis CompletedPendingTemporarily Closed (Paused) to Accrual and Study Agents/ProductsWithdrawn Sort Study Number AscStudy Number Desc Submit Search Showing 118 studies. A5257: Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers DAIDS Number 10670 Research Area Antiretroviral Strategies Study Status Participants Off Study and Primary Analysis Completed Locality United States A5241: Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US DAIDS Number 10395 Research Area Antiretroviral Strategies Study Status Concluded Locality United States IMPAACT 2035: A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of VPM1002 and BCG Re-Vaccination in Pre-Adolescents DAIDS Number TBA Research Area Tuberculosis Study Status In Development Locality Non-US IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Treatment Study Status Pending Locality United States IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV DAIDS Number TBD Research Area Treatment Study Status In Development Locality US & Non-US IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure Study Status Pending Locality US & Non-US IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Pending Locality US & Non-US IMPAACT 2024 : Phase I/II Dose Finding and Safety Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Infants, Children and Adolescents DAIDS Number 38747 Research Area Tuberculosis Study Status In Development Locality US & Non-US IMPAACT 2023: A Phase I Study of the Safety and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Treatment Study Status In Development Locality US & Non-US IMPAACT 2022: Phase II Study of the Virologic Efficacy and Feasibility of Long-Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV DAIDS Number 38631 Research Area Treatment Study Status In Development Locality United States Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 12 Next page Next
A5257: Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers DAIDS Number 10670 Research Area Antiretroviral Strategies Study Status Participants Off Study and Primary Analysis Completed Locality United States
A5241: Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US DAIDS Number 10395 Research Area Antiretroviral Strategies Study Status Concluded Locality United States
IMPAACT 2035: A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of VPM1002 and BCG Re-Vaccination in Pre-Adolescents DAIDS Number TBA Research Area Tuberculosis Study Status In Development Locality Non-US
IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Treatment Study Status Pending Locality United States
IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV DAIDS Number TBD Research Area Treatment Study Status In Development Locality US & Non-US
IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure Study Status Pending Locality US & Non-US
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Pending Locality US & Non-US
IMPAACT 2024 : Phase I/II Dose Finding and Safety Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Infants, Children and Adolescents DAIDS Number 38747 Research Area Tuberculosis Study Status In Development Locality US & Non-US
IMPAACT 2023: A Phase I Study of the Safety and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Treatment Study Status In Development Locality US & Non-US
IMPAACT 2022: Phase II Study of the Virologic Efficacy and Feasibility of Long-Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV DAIDS Number 38631 Research Area Treatment Study Status In Development Locality United States
